Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
ACXP
#4342
Acurx Pharmaceuticals, Inc. Common Stock
3.880
0
USD
-22.55%
Settore:
Salute
Base:
USD
Valuta di Profitto:
USD
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
-22.55%
Variazione Mensile
+102.08%
Variazione di 6 mesi
+102.08%
Variazione Annuale
+102.08%
Chiusura Precedente
5.010
0
Open
3.880
0
Bid
3.880
0
Ask
3.883
0
Low
3.880
0
High
3.880
0
Volume
12
Mercati
Mercato Azionario Statunitense
Salute
ACXP
Open full chart
Financials
Overview
Estratto Conto
Statistics
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2021
2022
2023
2024
2025
TTM
Cash from operating activities
-5.01 M
-7.54 M
-9.8 M
-10.38 M
-6.79 M
-6.79 M
Cash from investing activities
—
—
—
—
—
—
Cash from financing activities
14.8 M
3.7 M
8.16 M
6.62 M
10.64 M
10.64 M
Free cash flow
-5.01 M
-7.54 M
-9.8 M
-10.38 M
-6.79 M
-6.79 M
Notizie
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript
Relazione sugli utili: Acurx Pharmaceuticals Q4 2025 rivela liquidità rafforzata e progressi in R&S
Earnings call transcript: Acurx Pharmaceuticals Q4 2025 reveals cash boost and R&D progress
Le azioni di Acurx Pharmaceuticals guadagnano oltre il 3% con il lancio di un nuovo trial per l’rCDI
Acurx Pharmaceuticals stock gains over 3% on new rCDI trial launch
What's Going On With Acurx Pharmaceuticals Stock Today? - Acurx Pharmaceuticals (NASDAQ:ACXP)
Why Is Acurx Pharmaceuticals Stock Falling Thursday? - Acurx Pharmaceuticals (NASDAQ:ACXP)
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.61%
Why Is Acurx Pharmaceuticals Stock Up Over 105% Today? - Acurx Pharmaceuticals (NASDAQ:ACXP)
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript
Acurx’s ibezapolstat shows microbiome-sparing properties in trials